Company: REVB
Filing Date: 2025-03-06
Form Type: 10-K
Source: 0000950170-25-034584
Chunk: 172

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-03-06
Form: 10-K
Item: Item 1B
Chunk 172
---
: 

    Year EndedDecember 31,

    2024

    2023

    Change

    Operating expenses:

    Research and development
     
    $
    3,548,996

    $
    4,145,902

    $
    (596,906
    )

    General and administrative

    4,426,113

    4,510,762

    (84,649
    )

    Total operating expenses

    7,975,109

    8,656,664

    (681,555
    )

    Loss from operations

    (7,975,109
    )

    (8,656,664
    )

    681,555

    Total other (expense) income, net

    (7,063,427
    )

    8,536,410

    (15,599,837
    )

    Net loss
     
    $
    (15,038,536
    )
     
    $
    (120,254
    )
     
    $
    (14,918,282
    )

Research and Development Expenses

The following table summarizes our research and development expenses for the periods presented:

    Year EndedDecember 31,

    2024

    2023

    Change

    GEM-AKI, GEM-CKD and GEM-PSI clinical study expenses
     
    $
    1,681,731

    $
    209,702

    $
    1,472,029

    Manufacturing expenses

    390,022

    697,429

    (307,407
    )

    Other program expenses

    77,679

    2,190,493

    (2,112,814
    )

    Other expenses

    172,369

    282,948

    (110,579
    )

    Personnel expenses (including stock-based compensation)

    1,227,195

    765,330

    461,865

    Total research and development expenses
     
    $
    3,548,996

    $
    4,145,902

    $
    (596,906
    )

Research and development expenses decreased by $0.6 million, from $4.1 million for the year ended December 31, 2023 to $3.5 million for the year ended December 31,